NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









VenomAid Diagnostics

VenomAid Diagnostics

Private
CopenhagenHealthcare & Life Scienceshttps://www.venomaid.com/

Last Round

Seed

Jan 30, 2024

Total Funding Raised

$1.98M

Company Overview

VenomAid Diagnostics is a medtech company developing affordable, rapid diagnostic tests to identify snake venom and guide appropriate treatment.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology

Business Model

B2G

Customer Profile

Hardware Sales, Government Contracts

AI Layer

Non-AI

Keywords

snakebite diagnosticsrapid diagnostic testRDTpoint-of-care diagnosticsPOC diagnosticslateral flow assayLFAvenom detectionin-vitro diagnosticIVDMedTechneglected tropical diseasesNTDglobal healthmonoclonal antibodymedical device

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

VenomAid Diagnostics Comparables

Compare VenomAid Diagnostics with similar companies based on industry and business-model similarity.

VenomAid Diagnostics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
miprolab GmbH
76%
CSL Ltd
63%
Access Bio, Inc.
62%

VenomAid Diagnostics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJan 30, 2024
SeedJan 25, 2023
GrantJan 20, 2022
GrantJul 3, 2020

Key People

Founding team and executive leadership

Jonas Arnold Jürgensen-Breum

Co-founder & CEO

Founding Team

Gina Ross

Chief Technology Officer

Executive Team

VenomAid Diagnostics Investors

Notable investors and investment history

VenomAid Diagnostics investors
InvestorRounds
Innovation Fund DenmarkGrant
Novo Nordisk FoundationGrant
Good VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 30, 2024

    $800K raised with participation from Good Ventures.

  • Jan 25, 2023

    $1M round with participation from Good Ventures

VenomAid Diagnostics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

VenomAid Diagnostics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about VenomAid Diagnostics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCopenhagen
Employee Range12
Year Founded2018
Last FundingJan 30, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.